The rapid release of new trial results for sodium-glucose cotransporter 2 inhibitor (SGLT2i) and emerging indications demonstrate an exciting new treatment for patients at high cardiovascular risk. Join this expert-led session to gain insights on the latest science and practical applications you need to deliver cutting-edge therapy to your patients.

Webinar

Join chair Alison Bailey, MD, FACC, and expert faculty Javed Butler, MBBS, FACC, Michelle Kittleson, MD, FACC, and Deepak L. Bhatt, MD, MPH, FACC for a virtual session to gain insights on the latest science and practical applications you need to deliver cutting-edge therapy to your patients.

 
Certified Patient Cases

Apply your knowledge of SGLT2i’s and their role in CV risk reduction for high risk patients through these certified patient cases.

  • Coming Soon
 



Click here to see additional Spotlight Topics in the Clinical Spotlight Series

We are grateful to these distinguished Members of the American College of Cardiology who contributed to this collection:

Alison Bailey, MD, FAC

Javed Butler, MBBS, FACC

Michelle Kittleson, MD, FACC

Deepak L. Bhatt, MD, MPH, FACC

Supported by: Educational grants from AstraZeneca and Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC
Powered By